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Introduction
The prognosis for younger patients with mantle cell lym-
phoma (MCL) has improved in the recent decades due to 
intensified frontline regimens and rituximab maintenance.1-4 
The Nordic Lymphoma Group conducted 2 trials of inten-
sive cytarabine-containing frontline regimens and autologous 
stem cell transplantation (ASCT), the MCL2 and MCL3 tri-
als,1,5 of which the long-term follow-up of MCL2 showed a 
median overall survival (OS) exceeding 12 years.6 However, 
relapses occurred gradually throughout the entire follow-up 
period, even beyond 10 years of remission, suggesting that 
MCL is incurable by chemoimmunotherapy. At time of 
relapse, no standard of care exists, and the prognosis is poor 
despite the increasing use of novel agents such as ibrutinib.7-9 
In cohorts of younger patients treated by intensive frontline 
regimens, Visco et al8 showed a notable prognostic impact 
of time to progression of disease (POD) with a cut-off at 24 
months from start of first treatment. Similar results were pre-
sented by Kumar et al,7 although in a more heterogeneous 
cohort and with a cut-off of 12 months. However, informa-
tion on regimens used at the time of POD in these studies 
was limited.
Here, we present the results of a multicentre, retrospective 
cohort study of patients who relapsed or progressed after initial 
treatment in the 2 prospective Nordic Lymphoma Group trials, 
MCL2 and MCL3, both representing current standard of care 
regimens for younger patients with newly diagnosed MCL.
Methods
Patients
We conducted a retrospective cohort study of all 149 patients 
with POD after initial treatment in the Nordic MCL trials, 
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MCL2 and MCL3 (Figure 1A). Primary treatment of patients 
has been described elsewhere.1,5 Briefly, 319 patients younger 
than 66 years of age received an induction consisting of ritux-
imab and 6 alternating courses of maxi-CHOP (cyclophospha-
mide, doxorubicin, vincristine, and prednisolone) and high-dose 
cytarabine followed by stem cell harvest and consolidation 
with high-dose chemotherapy, BEAM/C (carmustine, etoposide, 
Ara-C, and melphalan/cyclophosphamide). During follow-up, 
patients with minimal residual disease markers (n = 183) who 
experienced molecular relapses with no concomitant clinical 
relapse were treated pre-emptively with 4 cycles of rituximab. 
Only clinical relapses are included in this study.
Figure 1. Overview and outcome of patients from the MCL2 and MCL3 trials after POD. (A) Flow chart showing the study cohort. (B) OS and (C) PFS 
in relation to line of therapy measured from time of disease progression and time of treatment start, respectively (In [A], total number of patients is included; 
in [B], all patients with known POD and death dates; and in [C], all patients with known dates of treatment start and of next POD if any). AlloSCT = allogeneic 
stem cell transplantation, ASCT = autologous stem cell transplantation, OS = overall survival, PFS = progression-free survival, POD = progression of disease.
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Information on later lines of therapy was collected by contact 
to the local treating physician with March 2019 being the latest 
follow-up date. Of all 149 patients with POD, information on 
second, third, and fourth-line therapy was available for 122, 77, 
and 52, respectively (Figure  1A). Of note, complete informa-
tion on treatment dates and follow-up was not available for all, 
and hence, the numbers do not add up for all the subsequent 
response and outcome analyses.
MCL international prognostic index (MIPI) was calculated 
according to Hoster et al.10 Mutations of TP53 were analyzed 
by next-generation sequencing of diagnostic bone marrow or 
lymph node samples according to the previous study by the 
Nordic MCL group.11
Statistics
Response evaluations were performed by the treating physi-
cian according to local guidelines. OS was measured from time 
of relapse to death of any cause. Progression-free survival (PFS) 
was measured from start of salvage therapy to next documented 
POD or death of any cause, and patients were censored at time 
of allogeneic stem cell transplantation (AlloSCT). Both OS and 
PFS were estimated by the Kaplan-Meier method, and compar-
ison of covariables was done by the log-rank test. Time to pro-
gression (TTP) was measured from start of last line of therapy 
to POD. To evaluate the prognostic impact of TTP following 
frontline treatment, we used TTP in a separate Cox regression 
model and then plotted the predicted hazard ratios using a cubic 
spline model.
For multivariable comparisons, Cox regression was used. 
MIPI score and cell proliferation marker (Ki67) were included 
as continuous variables, and blastoid morphology and TP53-
mutations as bimodal variables. Each variable was adjusted sep-
arately for the bimodal variable of early relapse (POD before 24 
months [POD24]). Chi-square and Fisher exact test were used 
to compare categorical variables, as appropriate, and Spearman 
correlation was used to evaluate the relationship between con-
tinuous variables. All P values were 2-tailed, and statistical 
significance was defined as P < 0.05. Statistical analyses were 
performed in SPSS 22.0 for Windows, GraphPad Prism 7.02 for 
Windows, and R (version 3.5.2).
Results
Patient characteristics
Of 319 patients included in the 2 prospective trials, MCL2 
and MCL3, for patients younger than 66 years of age with newly 
diagnosed MCL from 2000 to 2009,1,5 a total of 149 patients had 
POD between April 2001 and March 2019 (Figure 1A). Median 
age at relapse was 61 (interquartile range [IQR] 57-65) and 78% 
were males. Of 118 patients with available information, 7 (6%) 
had central nervous system involvement at POD (Table 1). MIPI 
status was available for 82 patients with 38 (46%) being low 
risk, 19 (23%) intermediate risk, and 25 (30%) high risk. There 
was a significant correlation of MIPI measured at diagnosis and 
at time of POD (ρ = 0.36 [95% CI = 0.15-0.54], P = 0.0008, 
Spearman’s correlation; Supplementary Figure 1, http://links.
lww.com/HS/A121). Seventeen (40%) had Ki67 below 30% and 
26 (60%) above 30% at time of POD. Like MIPI, Ki67 expres-
sion correlated significantly between diagnosis and time of POD 
(ρ = 0.67 [95% CI = 0.42-0.83], P < 0.001, Spearman’s correla-
tion; Supplementary Figure 2, http://links.lww.com/HS/A121).
Outcome after POD
With a median follow-up of 85 months for all 149 patients, 
the median OS from time of POD was 22 months (IQR = 9-73; 
Figure  1B). Obviously, OS decreased with subsequent PODs, 
that is, median OS was 11 months (IQR  =  3-52), 8 months 
(IQR = 2-28), and 6 months (IQR = 2-16) after second, third, 
and fourth relapse, respectively (Figure 1B). Similarly, median 
PFS from start of relapse therapy decreased with subsequent 
lines of therapy; median PFS after second line was 8.6 months 
(IQR = 2.6-25), after third line 7.4 months (IQR = 1.3-16), and 
after fourth line 3.6 months (IQR = 1.4-7.3; Figure 1C). Finally, 
responses to therapy decreased over time with 96%, 67%, 43%, 
and 44% achieving complete or partial responses at first, second, 
third, and fourth line of therapy, respectively (Supplementary 
Figure 3, http://links.lww.com/HS/A121).
POD before 24 months
Visco et al8 recently showed that TTP was highly prog-
nostic with a cut-off at 24 months (POD within 24 months, 
POD24). In our study, median TTP from frontline therapy was 
33 months (IQR = 16-60, Figure 2A), and 24 months seemed a 
reasonable cut-off both by an intention-to-treat approach in all 
149 patients (Figure 2B) and when focusing solely on the 126 
patients who underwent ASCT (Figure 2C). The hazard ratio for 
death decreased rapidly with TTP during the first 24-36 months 
and since remained almost constant for later relapses. Median 
OS from first POD was 6.6 (IQR  =  3.3-14) and 46 months 
(IQR = 18-95) in patients with early POD24 (n = 51, 34%) and 
later POD (n = 98, 66%), respectively (HR = 3.2 [95% CI = 3.0-
7.8], P < 0.001, log-rank; Figure 2D). Ten patients progressed 
before ASCT and had a median OS of 5.3 months (IQR = 2.3-
6.0; Supplementary Figure 4, http://links.lww.com/HS/A121), 
and 17 patients had POD later than 96 months and displayed a 
median OS of 55 months (IQR = 24-not reached).
For patients with available data on subsequent therapy, PFS 
from start of second line therapy was 2.3 (IQR = 1.6-4.3) and 
15 months (IQR  =  7-26) for patients with POD24 and later 
relapses, respectively (HR = 3.7 [95% CI = 2.1-6.4], P < 0.001, 
log-rank), and 2.2 months (IQR = 2.0-3.2) for primary refrac-
tory cases (Figure 2E, Supplementary Figure 5, http://links.lww.
com/HS/A121). Patients who did not undergo ASCT for other 
reasons than POD (toxicity n = 7; harvest failure n = 5; patient 
choice n  =  1) displayed a median OS and PFS of 40 and 19 
months, respectively (Supplementary Figures 4, 5, http://links.
lww.com/HS/A121).
Besides predicting for outcome and response to second line 
therapy, POD24 was significantly associated with inferior 
responses to all subsequent lines of therapy (Supplementary 
Figure 6, http://links.lww.com/HS/A121).
Other prognostic markers
Both MIPI risk group (available for 82) and Ki67 ≥30% 
(available for 41) at time of POD showed prognostic value for 
OS (P = 0.006 and P = 0.004, respectively, log-rank; Table 2, 
Figure 3A, B). Despite the low numbers, both biomarkers showed 
independent prognostic value when adjusted for POD24 in mul-
tivariable Cox regression analyses (P  =  0.0001 for MIPI and 
P = 0.11 for Ki67; Table 2). Due to missing data at time of POD, 
we investigated high-risk markers measured at time of diagno-
sis (MIPI, Ki67, blastoid morphology, and TP53 mutations). In 
line with their obvious association with early POD, each marker 
held prognostic value for outcome after POD (Figure  3C–F). 
Interestingly, each diagnostic biomarker also retained indepen-
dent prognostic impact after adjustment for POD24 (Table 2).
As an exploratory analysis, we combined the different bio-
markers to perform a combined risk score for the prognosis after 
POD. Each high-risk marker was assigned 1 point: MIPI high-
risk (either at diagnosis or relapse), Ki67 >30% (either at diagno-
sis or relapse), blastoid morphology at diagnosis, TP53 mutation 
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at diagnosis, and POD24. Despite the small numbers of each 
group, the analysis showed a clear separation of survival curves, 
and patients with 0, 1, 2-3, and 4-5 risk factors displayed 5-year 
OS of 62%, 39%, 31%, and 0%, respectively (Figure 3G).
Comparison of relapse regimens
Relapse regimens were based mainly on chemotherapy and 
rituximab and are summarized in Supplementary Table 1, http://
links.lww.com/HS/A121. We performed an exploratory compar-
ison of the efficacy of the different combination chemotherapy 
regimens based on central agents as outlined in Supplementary 
Table 1, http://links.lww.com/HS/A121 (excluding novel tar-
geted agents, low-dose/palliative regimens, monotherapy with 
rituximab or radiotherapy, and patients with central nervous 
system relapse; Supplementary Figure 7, http://links.lww.com/
HS/A121). Bendamustine and rituximab (BR) was adminis-
tered 38 times to 34 patients (5 times including also cytara-
bine [R-BAC], and once obinutuzumab instead of rituximab). 
Regardless of line of therapy, BR showed significantly prolonged 
PFS compared to all other combination regimens, most of which 
had higher toxicity profiles (Figure 4A–C, Supplementary Figure 
7, http://links.lww.com/HS/A121). R-BAC did not seem to per-
form better than BR alone, and hence, they are evaluated com-
bined (data not shown). In second line, overall response rate 
([ORR] as defined by partial response [PR] and complete remis-
sion [CR]) of patients treated with BR (n = 21) was 86% (CR 
57%) compared with an ORR of 54% (CR 30%) in patients 
treated with other rituximab-chemotherapy combinations reg-
imens (P = 0.01, χ2). A similar trend was present in third line 
with ORRs of 60% (CR 60%) and 26% (CR 9%) for 10 and 
23 patients, respectively (P = 0.063). In fourth line, ORR was 
67% (CR 33%) and 46% (CR 18%) for 6 and 10 patients, 
respectively (P  =  0.4). Importantly, administration of BR was 
also associated with a longer TTP from prior line of therapy, 
indicative of a lower risk disease. When adjusting for this in 
multivariable Cox regression analyses, BR no longer held pos-
itive predictive value for PFS. Only 4 patients with POD24 
received BR (Figure 4D).
Due to the calendar year of therapy, only a minority of 
patients received novel drugs. Seven patients received ibrutinib, 
hereof 4 in the PHILEMON study (ClinicalTrials.gov, number 
NCT02460276; ibruntinib, lenalidomide, and rituximab).12 
Compared with BR and other combination-regimens, the PFS 
for ibrutinib-containing regimens tended to be longer, despite 
Table 1
Patient Characteristics.
 All Patients Early POD, <24 mo Late POD, ≥24 mo
P n % n % n %
 149  51 34 98 66  
Sex        
 Female 32 21 9 18 23 23 0.41
 Male 117 79 42 82 75 77  
Trial        
 MCL2 78 52 26 51 52 53 0.81
 MCL3 71 48 25 49 46 47  
ASCT in front line        
 Yes 126 85 35 69 91 93 <0.001
 No 23 15 16 31 7 7  
At first POD:        
 Median age 61 (IQR 57-65)  61 (IQR 55-64)  61 (IQR 57-67)  0.14
 CNS involvement (n = 118)
  No 111 94 37 88 74 97 0.10
  Yes 7 6 5 12 2 3  
 MIPI (n = 82)        
  LR 38 46 9 41 29 48 0.17
  IR 19 23 3 14 16 27  
  HR 25 30 10 45 15 25  
 Ki67 (n = 43)        
  <30% 17 40 0 0 17 50 0.007
  ≥30% 26 60 9 100 17 50  
At diagnosis:
 Median age 57 (IQR 52-61)  59 (IQR 53-63)  56 (IQR 51-61)  0.036
 MIPI (n = 147)
  LR 57 39 9 18 48 49 <0.001
  IR 41 28 13 26 28 29  
  HR 49 33 28 56 21 22  
 Ki67 (n = 128)
  <30% 63 49 12 26 50 61 <0.001
  ≥30% 65 51 33 72 32 39  
 Blastoid (n = 149)
  No 115 77 29 57 86 88 <0.001
  Yes 34 23 22 43 12 12  
 TP53 mutated (n = 94)
  No 69 73 12 40 57 89 <0.001
  Yes 25 27 18 60 7 11  
ASCT = autologous stem cell transplantation, CNS = central nervous system, HR = high-risk, IR = intermediate-risk, Ki67 = cell proliferation marker, LR = low-risk, MIPI = mantle cell lymphoma interna-
tional prognostic index, POD = progression of disease.
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being administered in later lines of therapy and with a shorter 
time from last line of therapy (Figure 4E).
Among patients with POD24, no single regimen showed supe-
rior response, and only 3 patients received ibrutinib. Similarly, 
for patients carrying other high-risk markers such as TP53 muta-
tions, no single regimen was associated with superior responses.
Allogeneic stem cell transplantation
Of the 149 relapsed patients, a total of 25 (17%) underwent 
AlloSCT. Median age at time of transplant was 56, and 17 were 
transplanted after second line therapy, 6 after third line, and 2 
after fourth line. With a median follow-up of 82 months from time 
of AlloSCT, the median OS and PFS was 61.4 (IQR = 18-104) and 
33.5 months (IQR = 9-90), respectively (Figure 5A, B). After 2 
years, 18% of patients had experienced MCL relapses, whereas 
29% had died from MCL unrelated reasons mainly associated 
with treatment-related toxicity (Figure 5C). Among the AlloSCT 
patients, the presence of high-risk markers was significantly lower 
than in nontransplanted patients. Only 3 patients with POD24 
underwent AlloSCT, and they all displayed rapid progression 
after transplantation (PFS 1, 4, and 9 months, respectively); how-
ever, one of these patients since achieved a long-term remission 
after local radiotherapy. These 3 patients all had TP53 mutations 
Figure 2. Time to POD as a prognostic marker for outcome after POD. (A), The time to first POD for all MCL2 and MCL3 with documented POD. (B), 
Spline curve showing the predicted hazard ratio of time to POD from start of frontline treatment as a prognostic marker. (C), Spline curve for patients who under-
went ASCT. (D), OS and (E), PFS according to POD before or after 24 mo (POD24). ASCT = autologous stem cell transplantation, MCL = mantle cell lymphoma, 
OS = overall survival, PFS = progression-free survival, POD = progression of disease.
Table 2
Multivariable Cox Regression Analyses for OS After POD, 
Adjusted for POD24.
    OS   





At relapse       
 MIPI 82 None 2.68 1.75 4.11 <0.0001
  POD24 2.36 1.53 3.65 0.0001
 Ki67 >30% 41 None 3.66 1.46 9.16 0.006
  POD24 2.90 1.10 7.65 0.032
At diagnosis       
 MIPI 147 None 2.03 1.63 2.54 <0.0001
  POD24 1.86 1.48 2.34 <0.0001
 Ki67 >30% 128 None 2.25 1.48 3.42 0.0001
  POD24 1.87 1.22 2.87 0.004
 Blastoid 149 None 3.21 2.07 4.98 <0.0001
  POD24 2.84 1.80 4.49 <0.0001
 TP53 mutations 92 None 2.81 1.67 4.73 0.0001
  POD24 1.81 0.97 3.40 0.064
CI = confidence interval, HR = hazard ratio, Ki67 = cell proliferation marker, MIPI = mantle cell 
lymphoma international prognostic index, OS = overall survival, POD24 = progression of disease 
before 24 mo from start of frontline treatment.
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Figure 3. OS after POD according to prognostic biomarkers. (A) MIPI risk groups and (B) Ki67 expression measured at time of POD. (C) MIPI risk groups, 
(D) Ki67 expression, (E) blastoid morphology, and (F) TP53 mutational status measures at diagnosis. (G) OS according to number of risk factor measured either 
at POD or diagnosis (POD24, MIPI high risk, Ki67 ≥30%, blastoid morphology, and TP53 mutations). HR = high-risk, IR = intermediate-risk, Ki67 = cell prolifer-
ation marker, LR = low-risk, MIPI = mantle cell lymphoma international prognostic index, OS = overall survival, POD = progression of disease.
Figure 4. PFS according to relapse treatment. BR compared to other Comb. chemo regimens at (A) second line, (B) third line, (C) fourth line, and (D) 
displays BR vs Comb. chemo at all lines of therapy stratified by early and late POD (cut off 24 mo). (E) All lines of therapy compiled and stratified by BR, ibruti-
nib-containing, and other combination chemotherapy (In [D] and [E], each patient is only included once with the earliest line of treatment). BR = bendamustin-rit-
uxumab, Comb. chemo = combination chemotherapy, PFS = progression-free survival, POD = progression of disease.
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at diagnosis, compared to none of 15 other AlloSCT patients with 
available diagnostic sample for mutational analysis.
Discussion
We present the results of postrelapse outcomes of patients 
included in the 2 prospective Nordic MCL trials, MCL2 and 
MCL3, for patients younger than 66 years of age. We confirm 
the impact of POD24 as a prognostic and predictive marker, and 
we show that well-known prognostic markers measured both 
at diagnosis and at time of relapse retain prognostic value inde-
pendently of POD24.
Stratifying patients at relapse may be used to allocate 
patients of different risk profiles to different salvage regimens. 
Especially, to choose between repetition of chemoimmunother-
apy or attempting novel targeted agents, and subsequently, if 
the patient should proceed to an allogeneic transplantation. 
Due to the calendar year of most treatments in this study, most 
patients were not treated with novel targeted agents. However, 
it represents a long-term follow-up of the prospective cohort of 
patients treated by standard of care frontline regimens.
We confirmed the results by Visco et al8 that the POD24 
could be used as a prognostic discriminator of patients who 
were treated by intensive frontline regimens. Patients with 
POD24 displayed a median OS of 6.6 months compared with 
46 months for patients with later relapses. Similarly, treatment 
responses were highly different between the 2 groups, not only 
at second line but also subsequent lines of therapy.
By comparison of all combination chemotherapy regimens 
used in the relapse setting, BR performed better than all others 
despite a lower toxicity profile. However, administration of BR 
was also associated with longer remission after last line of ther-
apy, and hence, treatment groups were not comparable. Adjusting 
for response duration to last line of therapy, BR was no longer 
significantly better than other salvage regimens. Nonetheless, our 
results support the continued use of BR in patients with longer 
preceding remissions. Recently, BR alternating with high-dose 
cytarabine followed by ASCT also proved to be well tolerated 
and achieving high rates of durable remission in first line.13
Patients with POD24 displayed dismal outcomes and showed 
very poor response rates to all subsequent regimens. Hence, novel 
treatment approaches are warranted for this subset of patients. 
Ibrutinib has shown impressive overall responses in R/R MCL in 
general.14 However, still for ibrutinib, TTP impacts the responses 
and response durations markedly. Thus, this may not be suffi-
cient as a single agent for patients with early relapses.9
POD24 was not surprisingly associated with other known 
prognostic markers such as MIPI, Ki67, blastoid disease, and 
TP53 mutations. Despite this, each of these biomarkers also 
showed independent impact irrespective of POD24, and further-
more, this was true whether measured at initial diagnosis or at 
the time of POD. This illustrates the heterogeneity of MCL, that 
prognostic stratification from diagnosis will continue also after 
POD. In an exploratory analysis, we combined the different risk 
markers to perform a risk score for post-POD survival. Most 
importantly, we defined a low-risk group of which 62% were 
alive 5 years after first POD. This analysis was affected by miss-
ing data and small risk groups, and hence, it does not represent 
a model for future use. However, it shows the complexity and 
impact of many different prognostic biomarkers and supports 
a detailed evaluation of each patient to assess their risk pro-
file. It may identify patients with no high-risk markers and a 
very good prognosis, and other patients with many high-risk 
markers who will most likely not respond to conventional 
chemoimmunotherapy.
A total of 25 patients from our cohort underwent AlloSCT. 
With a median PFS of 33.5 months from time of transplantation 
and no clear survival plateau, the overall results were not sup-
portive of AlloSCT. This may be due to the relatively high rate 
of nonrelapse mortality, which has also been observed in other 
studies of AlloSCT in MCL.15 AlloSCT was of particular inter-
est in high-risk groups such as patients with early POD, since 
no other therapy has shown convincing results for this subset. 
However, only 3 patients with POD24 went on to AlloSCT and 
they displayed variable responses. The underrepresentation of 
early progressors may be due to the lack of durable responses 
needed to bridge the patients to transplantation.
One of the strongest prognosticators for MCL is mutations 
of TP53.11,16 Lin et al17 suggested a role of AlloSCT for these 
patients; however, in our study, only 3 patients with TP53 muta-
tions (all early POD) underwent AlloSCT, and all progressed 
again within 1 year of transplant. Prospective data are war-
ranted to evaluate the efficacy of AlloSCT in TP53 mutated 
patients. Importantly, Wang et al18 recently published that chi-
meric antigen receptor T-cell therapy was efficacious in relapsed 
MCL regardless of high-risk biomarkers; although they did 
not include TTP as a biomarker. This supports the use of such 
treatment already at first POD in high-risk patients, or for some 
maybe already at frontline. Even though ibrutinib may not over-
come the very high-risk MCLs such as early relapses and TP53 
mutated, it may serve as bridging strategy to therapies such as 
AlloSCT and chimeric antigen receptor T-cell (CAR-T).9,19
In this study, we mainly investigate the use of chemoimmu-
notherapies, and the results overall support the continued use 
of, for example, BR in patients with few risk factors present 
at relapse. However, as mentioned, there is an unmet need in 
patients with early POD or other high-risk markers. With many 
novel targeted therapies appearing, studies evaluating these in 
high-risk R/R MCL patients will be of high interest. Accordingly, 
the few cases of these novel therapies is an important limita-
tion to the current study. Furthermore, the retrospective nature 
of the study reduces the ability to compare different regimens 
across subgroups of patients. However, the predefined study 
cohort, that is, participation in the Nordic MCL2 and MCL3 
trials, increase the comparative.
In conclusion, this report displays the postrelapse outcomes 
of patients originally treated in the 2 Nordic MCL frontline 
trials consisting of intensive cytarabine-containing induction 
Figure 5. Outcome after AlloSCT. (A) OS, (B) progression-free survival, and (C) cumulative incidences of MCL relapses and MCL-unrelated deaths, respectively. 
AlloSCT = allogeneic stem cell transplantation, CR = complete remission, MCL = mantle cell lymphoma, OS = overall survival, PFS = progression-free survival.
8
Eskelund et al Follow-Up of Nordic MCL Patients After Relapse
therapy and ASCT. We confirm the prognostic impact of the 
POD24 which has been suggested by others, and we highlight 
the relevance of other known prognostic biomarkers, whether 
measured at diagnosis or re-evaluated at time of POD. Patients 
with early POD or other high-risk markers showed very poor 
responses and outcomes in general, and further studies explor-
ing novel treatment modalities are needed to guide handling of 
this subset.
Acknowledgments
The authors thank the medical and nursing staffs of all contribut-
ing departments to this study, and the patients for their willingness to 
participate.
Sources of funding
This study was supported by grants from the Independent Research 
Fund Denmark, the Novo Nordisk foundation, Rigshospitalet’s 
Research Foundation, Lundbeck Foundation, Danish Cancer Research 
Foundation. Furthermore, the K.G. lab is funded by center grants from 
the Danish Cancer Society (Danish Research Center for Precision 
Medicine in Blood Cancer; grant 223-A13071-18-S68), the Novo 
Nordisk Foundation (Novo Nordisk Foundation Center for Stem 
Cell Biology, DanStem; grant NNF17CC0027852), and the Greater 
Copenhagen Health Science Partners (Clinical Academic Group in 
Translational Hematology).
Disclosures
IG has received IG Honoraria from Janssen. CUN has received 
consultancy fees and/or travel grants from Janssen, Abbvie, Novartis, 
Roche, Sunesis, Gilead, AstraZeneca, and CSL Behring, and research 
funding from Novo Nordisk Foundation, grant NNF16OC0019302, 
Abbvie, AstraZeneca and Janssen, outside this project. All the other 
authors have no conflicts of interest to disclose.
References
1. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free 
survival of mantle cell lymphoma after intensive front-line immunoche-
motherapy with in vivo-purged stem cell rescue: a nonrandomized 
phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 
2008;112:2687–2693.
2. Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytara-
bine to immunochemotherapy before autologous stem-cell transplan-
tation in patients aged 65 years or younger with mantle cell lymphoma 
(MCL Younger): a randomised, open-label, phase 3 trial of the European 
Mantle Cell Lymphoma Network. Lancet. 2016;388:565–575.
3. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable 
remissions after treatment of newly diagnosed aggressive mantle-cell 
lymphoma with rituximab plus hyper-CVAD alternating with ritux-
imab plus high-dose methotrexate and cytarabine. J Clin Oncol. 
2005;23:7013–7023.
4. Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autol-
ogous stem-cell transplantation in mantle-cell lymphoma. N Engl J 
Med. 2017;377:1250–1260.
5. Kolstad A, Laurell A, Jerkeman M, et al. Nordic MCL3 study: 
90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before 
transplant in mantle cell lymphoma. Blood. 2014;123:2953–2959.
6. Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the 
second nordic mantle cell lymphoma trial (MCL2): prolonged remis-
sions without survival plateau. Br J Haematol. 2016;175:410–418.
7. Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with 
recurrent mantle cell lymphoma in the modern era: progressive short-
ening in response duration and survival after each relapse. Blood 
Cancer J. 2019;9:50.
8. Visco C, Tisi MC, Evangelista A, et al. Time to progression of mantle 
cell lymphoma after high-dose cytarabine-based regimens defines 
patients risk for death. Br J Haematol. 2019;185:940–944.
9. Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/
refractory mantle cell lymphoma: extended 3.5-year follow up from a 
pooled analysis. Haematologica. 2019;104:e211–e214.
10. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) 
for patients with advanced-stage mantle cell lymphoma. Blood. 
2008;111:558–565.
11. Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify 
younger mantle cell lymphoma patients who do not benefit from 
intensive chemoimmunotherapy. Blood. 2017;130:1903–1910.
12. Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalido-
mide, and rituximab in relapsed or refractory mantle cell lymphoma 
(PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. 
Lancet Haematol. 2018;5:e109–e116.
13. Merryman RW, Edwin N, Redd R, et al. Rituximab/bendamustine and 
rituximab/cytarabine induction therapy for transplant-eligible mantle 
cell lymphoma. Blood Adv. 2020;4:858–867.
14. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib 
in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 
2013;369:507–516.
15. Tessoulin B, Ceballos P, Chevallier P, et al. Allogeneic stem cell trans-
plantation for patients with mantle cell lymphoma who failed autol-
ogous stem cell transplantation: a national survey of the SFGM-TC. 
Bone Marrow Transplant. 2016;51:1184–1190.
16. Ferrero S, Rossi D, Rinaldi A, et al. KMT2D mutations and TP53 
disruptions are poor prognostic biomarkers in mantle cell lym-
phoma receiving high-dose therapy: a FIL study. Haematologica. 
2020;105:1604–1612.
17. Lin RJ, Ho C, Hilden PD, et al. Allogeneic haematopoietic cell trans-
plantation impacts on outcomes of mantle cell lymphoma with TP53 
alterations. Br J Haematol. 2019;184:1006–1010.
18. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy 
in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 
2020;382:1331–1342.
19. Dreger P, Michallet M, Bosman P, et al. Ibrutinib for bridging to alloge-
neic hematopoietic cell transplantation in patients with chronic lym-
phocytic leukemia or mantle cell lymphoma: a study by the EBMT 
Chronic Malignancies and Lymphoma Working Parties. Bone Marrow 
Transplant. 2019;54:44–52.
